133 related articles for article (PubMed ID: 23815443)
1. Targeted delivery of Epirubicin to cancer cells by PEGylated A10 aptamer.
Taghdisi SM; Danesh NM; Sarreshtehdar Emrani A; Tabrizian K; Zandkarimi M; Ramezani M; Abnous K
J Drug Target; 2013 Sep; 21(8):739-44. PubMed ID: 23815443
[TBL] [Abstract][Full Text] [Related]
2. Double targeting and aptamer-assisted controlled release delivery of epirubicin to cancer cells by aptamers-based dendrimer in vitro and in vivo.
Taghdisi SM; Danesh NM; Ramezani M; Lavaee P; Jalalian SH; Robati RY; Abnous K
Eur J Pharm Biopharm; 2016 May; 102():152-8. PubMed ID: 26987703
[TBL] [Abstract][Full Text] [Related]
3. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
[TBL] [Abstract][Full Text] [Related]
4. Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo.
Jalalian SH; Taghdisi SM; Shahidi Hamedani N; Kalat SA; Lavaee P; Zandkarimi M; Ghows N; Jaafari MR; Naghibi S; Danesh NM; Ramezani M; Abnous K
Eur J Pharm Sci; 2013 Oct; 50(2):191-7. PubMed ID: 23835028
[TBL] [Abstract][Full Text] [Related]
5. A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo.
Bahreyni A; Alibolandi M; Ramezani M; Sarafan Sadeghi A; Abnous K; Taghdisi SM
Colloids Surf B Biointerfaces; 2019 Mar; 175():231-238. PubMed ID: 30537619
[TBL] [Abstract][Full Text] [Related]
6. Targeted Delivery of Epirubicin to Cancer Cells by Polyvalent Aptamer System in vitro and in vivo.
Yazdian-Robati R; Ramezani M; Jalalian SH; Abnous K; Taghdisi SM
Pharm Res; 2016 Sep; 33(9):2289-97. PubMed ID: 27283831
[TBL] [Abstract][Full Text] [Related]
7. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.
Dhar S; Gu FX; Langer R; Farokhzad OC; Lippard SJ
Proc Natl Acad Sci U S A; 2008 Nov; 105(45):17356-61. PubMed ID: 18978032
[TBL] [Abstract][Full Text] [Related]
9. Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo.
Hao Z; Fan W; Hao J; Wu X; Zeng GQ; Zhang LJ; Nie SF; Wang XD
Drug Deliv; 2016; 23(3):874-81. PubMed ID: 24892627
[TBL] [Abstract][Full Text] [Related]
10. Targeted co-delivery of epirubicin and NAS-24 aptamer to cancer cells using selenium nanoparticles for enhancing tumor response in vitro and in vivo.
Jalalian SH; Ramezani M; Abnous K; Taghdisi SM
Cancer Lett; 2018 Mar; 416():87-93. PubMed ID: 29253524
[TBL] [Abstract][Full Text] [Related]
11. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE
J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex.
Kim E; Jung Y; Choi H; Yang J; Suh JS; Huh YM; Kim K; Haam S
Biomaterials; 2010 Jun; 31(16):4592-9. PubMed ID: 20206379
[TBL] [Abstract][Full Text] [Related]
13. Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro.
Alibolandi M; Ramezani M; Sadeghi F; Abnous K; Hadizadeh F
Int J Pharm; 2015 Feb; 479(1):241-51. PubMed ID: 25529433
[TBL] [Abstract][Full Text] [Related]
14. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
Farokhzad OC; Cheng J; Teply BA; Sherifi I; Jon S; Kantoff PW; Richie JP; Langer R
Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6315-20. PubMed ID: 16606824
[TBL] [Abstract][Full Text] [Related]
15. A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery.
Leach JC; Wang A; Ye K; Jin S
Int J Mol Sci; 2016 Mar; 17(3):380. PubMed ID: 26985893
[TBL] [Abstract][Full Text] [Related]
16. Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system.
Jing P; Cao S; Xiao S; Zhang X; Ke S; Ke F; Yu X; Wang L; Wang S; Luo Y; Zhong Z
Cancer Lett; 2016 Dec; 383(2):230-242. PubMed ID: 27721020
[TBL] [Abstract][Full Text] [Related]
17. Aptamer-mediated delivery of docetaxel to prostate cancer through polymeric nanoparticles for enhancement of antitumor efficacy.
Chen Z; Tai Z; Gu F; Hu C; Zhu Q; Gao S
Eur J Pharm Biopharm; 2016 Oct; 107():130-41. PubMed ID: 27393562
[TBL] [Abstract][Full Text] [Related]
18. Targeted and controlled release delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer-modified gold nanoparticles.
Danesh NM; Lavaee P; Ramezani M; Abnous K; Taghdisi SM
Int J Pharm; 2015 Jul; 489(1-2):311-7. PubMed ID: 25936625
[TBL] [Abstract][Full Text] [Related]
19. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.
Cheng J; Teply BA; Sherifi I; Sung J; Luther G; Gu FX; Levy-Nissenbaum E; Radovic-Moreno AF; Langer R; Farokhzad OC
Biomaterials; 2007 Feb; 28(5):869-76. PubMed ID: 17055572
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer.
Taghdisi SM; Abnous K; Mosaffa F; Behravan J
J Drug Target; 2010 May; 18(4):277-81. PubMed ID: 19943768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
